Literature DB >> 22425318

Progestin-only contraception and venous thromboembolism.

M A Blanco-Molina1, M Lozano, A Cano, I Cristobal, L P Pallardo, I Lete.   

Abstract

Combined oral contraceptives (COC) are the most popular contraceptive method in developed countries. Since their introduction there have been numerous changes and modifications in its composition with the aim to improve safety and tolerability while maintaining contraceptive efficacy. Most of the changes have been conducted on the progestin component, since most of the combinations include ethinyl estradiol as oestrogen. One of the adverse effects of COC is the increased risk of venous thromboembolism (VTE) in two clinical forms of presentation: deep vein thrombosis or pulmonary embolism. This review details the changes in haemostasis induced by progestin-only contraceptives and the risk of VTE in women who utilize this type of contraception; the relationship with other risk factors such as thrombophilia; the interactions of these contraceptives with anticoagulant treatment and finally the eligibility criteria for the use of hormonal contraception in women with previous VTE or thrombophilia carriers.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425318     DOI: 10.1016/j.thromres.2012.02.042

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

Review 1.  A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.

Authors:  Monica V Dragoman; Naomi K Tepper; Rongwei Fu; Kathryn M Curtis; Roger Chou; Mary E Gaffield
Journal:  Int J Gynaecol Obstet       Date:  2018-02-22       Impact factor: 3.561

Review 2.  Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk.

Authors:  Laure Morimont; Hélène Haguet; Jean-Michel Dogné; Ulysse Gaspard; Jonathan Douxfils
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.